On January 10, 1992, the sea was awash with yellow ducks, blue tortoises, green frogs and red beavers. A container filled with 29,000 bath toys had fallen off a ship during a violent storm in the North Pacific, almost exactly halfway between Asia and America. Seven months later, hundreds of the rubber toys were deposited on the coast of Sitka, Alaska, not far away from where some 61,000 Nike sneakers had washed up after a similar accident at sea two years earlier. It then occurred to American oceanographer Curtis Ebbesmeyer that these drifting objects could be studied over a number of years to predict ocean currents.
Researchers from the Institute of Mathematical Sciences (ICMAT) and the Polytechnic University of Catalonia have managed to design an abstract structure that
All licensed vaccines are extremely effective in preventing severe cases of Covid-19, a disease that has killed around three million people worldwide in the space of one year. However, there are still individuals who are more afraid of the vaccine than of the virus. The focus now is on the Oxford-AstraZeneca and Janssen vaccines, after dozens of those who were vaccinated Ââ about 1 in 100,000 â developed a very rare form of potentially lethal blood clots.
Below is a sample of risk-versus-benefit calculations. While approximate, they are useful for understanding the kind of figures used by drug regulatory agencies. We start by looking at a general scenario of 100,000 adults of all ages over a period of four months with an incidence of Covid-19 that reflects the rates experienced in 2021 in Spain:
News
TECNALIA ranked third in the list of Spanish organisations that applied for the most European patents in 2020
7 April 2021
TECNALIA has a portfolio of 192 patent families (783 patents) and 13 investee companies, which create 207 direct jobs.
For the fifth consecutive year, TECNALIA was once again one of the top organisations in Spain in terms of the number of applications for European patents (click here for the historical record).
Specifically, TECNALIA came in in third place with 17 European patent applications, behind CSIC (72) and Amadeus (60), the same as Laboratorios Esteve (17) and Telefónica (17) and ahead of the Polytechnic University of Catalonia (15), Repsol (14) and Pharma Mar (14), among others.